BIOCRYST PHARMACEUTICALS INC (BCRX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-07

Key Insights

Sandeep Menon, the Chief R&D Officer, has received a significant inducement grant of 205,150 restricted stock units and 441,350 stock options, indicating the company's commitment to R&D efforts and incentivizing the executive's long-term involvement.
The option grant has a 10-year term and vests over 4 years, aligning Menon's interests with long-term shareholder value creation.
The sizeable insider stock acquisition suggests Menon's confidence in the company's future prospects and may signal positive sentiment about the company's R&D pipeline and growth potential.

Want the newest filings?

This analysis covers the filing from 2026-04-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-24

Theresa Heggie, a director at BioCryst Pharmaceuticals, exercised 49,933 stock options and sold the same amount of shares on March 20, 2026.
The stock options were exercised at $6.30 per share, and the shares were sold at a weighted average price of $10.11 per share, indicating potential profit-taking.
The transaction resulted in Heggie's direct ownership decreasing from 115,285 shares to 65,352 shares, a 43% reduction in her direct holdings.

Filed: 2026-03-18

The reporting person, Alane P. Barnes, exercised 150,000 stock options and sold the same number of shares in a planned transaction, indicating an ongoing equity incentive program at the company.
The sale was executed at a weighted average price of $9.15, which represents a gain of over 60% from the $5.51 exercise price, suggesting the stock has been performing well.
The reporting person continues to hold a significant stake of 400,703 shares in the company, indicating their commitment to the long-term success of the business.

Filed: 2026-03-03

The reporting person, Amy E. McKee, acquired 642 shares of common stock in BIOCRYST PHARMACEUTICALS INC (BCRX) on February 27, 2026, which increased her direct ownership to 42,432 shares.
This share acquisition was made in lieu of 50% of the quarterly cash board member retainer, suggesting the reporting person's continued commitment to the company.
The transaction price of $8.75 per share indicates the reporting person's confidence in the company's valuation and future prospects.

Filed: 2026-03-03

The reporting person, Steven Frank, acquired 1,285 shares of BiocrystPharmaceuticals common stock on February 27, 2026, increasing his direct beneficial ownership to 18,903 shares.
The shares were acquired in lieu of 100% of his quarterly cash board member retainer of $11,250, indicating his commitment to the company.
Insider buying, especially by a director, can be a positive signal about the company's prospects and the director's confidence in the stock.

Filed: 2026-03-03

The reporting person, Vincent Milano, has acquired 848 shares of BiocrystPharmaceuticals common stock, increasing his direct ownership to 92,067 shares.
The shares were acquired in lieu of 50% of Milano's quarterly cash board retainer and board chair retainer, suggesting he is compensated partially in stock.
Insider buying by a director can signal confidence in the company's future performance and may be viewed positively by investors.

Filed: 2026-03-03

Insider Jon P. Stonehouse, a director of BioDecryst Pharmaceuticals, has engaged in a significant transaction involving the company's stock, including exercising stock options and selling shares.
Stonehouse exercised 305,995 stock options at a price of $3.22 and then sold the same number of shares at a weighted average price of $8.64, generating substantial gains.
The transaction appears to be part of a pre-established trading plan, suggesting it may not be a discretionary trade, but rather an automated execution based on a previously established plan.

Filed: 2026-03-03

Jill C. Milne, a director of BioCryst Pharmaceuticals, acquired 528 shares of common stock through a transaction on 2/27/2026, increasing her direct ownership to 15,382 shares.
The shares were acquired at $8.75 per share, which appears to be a standard non-cash compensation for the director's board retainer.
Insider transactions can provide insights into management's confidence in the company's prospects, though a single purchase should not be over-interpreted.

Filed: 2026-01-27

Jill C. Milne, a director of BioCryst Pharmaceuticals, acquired additional shares of the company's common stock through an automatic non-employee director grant, indicating ongoing commitment to the organization.
The acquisition of Astria Therapeutics resulted in Milne receiving 2,582 shares of BioCryst common stock in exchange for her Astria shares, further increasing her ownership stake.
The automatic grant of 26,684 stock options to Milne, vesting over a 3-year period, aligns her incentives with long-term shareholder value creation.

Other reports for BIOCRYST PHARMACEUTICALS INC

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.